Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: CRIB (CNTF delivery) CytoTherapeutics Inc.

A Abicht1, H Lochmüller

  • 1Genzentrum und Friedrich-Baur-Institut, Ludwig-Maximilians-Universität, Feodor-Lynen-Strasse 25, 81377, Münich, Germany.

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary

This study presents a novel device for continuous, site-specific delivery of therapeutic molecules to the central nervous system (CNS). The technology uses genetically modified xenogenic cells encapsulated in polymer fibers, showing promise for treating neurological conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In response to Gulcin Akinci's and Haluk Topaloglu's letter regarding our article "Predictors of loss of ambulation in Duchenne muscular dystrophy: A systematic review and meta-analysis".

Journal of neuromuscular diseases·2025
Same author

Predictors of Loss of Ambulation in Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.

Journal of neuromuscular diseases·2024
Same author

Factors Associated with Respiratory Health and Function in Duchenne Muscular Dystrophy: A Systematic Review and Evidence Grading.

Journal of neuromuscular diseases·2023
Same author

Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada.

Journal of neuromuscular diseases·2021
Same author

Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a 'Treatabolome'.

Journal of neuromuscular diseases·2021
Same author

The Canadian Neuromuscular Disease Registry 2010-2019: A Decade of Facilitating Clinical Research Througha Nationwide, Pan-NeuromuscularDisease Registry.

Journal of neuromuscular diseases·2020

Area of Science:

  • Biotechnology
  • Neuroscience
  • Drug Delivery Systems

Background:

  • Continuous, site-specific delivery of therapeutics to the central nervous system (CNS) remains a significant challenge.
  • Existing methods often face limitations in efficacy and immune response.
  • The need for advanced delivery systems for neurological disorders is critical.

Purpose of the Study:

  • To develop and evaluate a novel therapeutic approach for continuous, site-specific CNS delivery.
  • To investigate the use of genetically modified xenogenic cells encapsulated in polymer fibers for therapeutic molecule secretion.
  • To assess the potential of this system in preclinical and early clinical settings.

Main Methods:

  • In vitro gene transfer was combined with a novel delivery device utilizing polymer-based fibers.

Related Experiment Videos

  • Xenogenic cells were genetically modified to secrete specific bioactive substances.
  • A semipermeable membrane was employed to regulate molecular exchange and immune response.

    • Main Results:

    • The technique successfully demonstrated in vitro and in vivo delivery of various therapeutic agents, including neurotrophic factors, neurotransmitters, and hormones.
    • The semipermeable membrane facilitated xenograft survival by controlling nutrient passage and immune cell diffusion.
    • Phase I clinical trials were initiated for amyotrophic lateral sclerosis (ALS) and chronic cancer pain.

    Conclusions:

    • This novel technique offers a promising strategy for continuous, site-specific therapeutic delivery to the CNS.
    • The encapsulated xenogenic cell system effectively delivers bioactive substances while mitigating immune rejection.
    • Early clinical trials suggest potential applications in treating debilitating neurological conditions like ALS and chronic pain.